secwatch.observer — SEC 8-K summary
======================================

Issuer:     Marker Therapeutics, Inc. (MRKR)
CIK:        0001094038
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001104659-23-091425
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Marker Therapeutics Q2 net income $2.5M; Cell Ready deal extends cash runway into Q4 2025
--------------------------------------------------------------------------------

- Net income of $2.5M vs net loss of $9.2M in Q2 2022; cash and equivalents $18.1M.
- Non-dilutive agreement with Cell Ready provides ~$19M cash and reduces annual operating expenses by ~$11M.
- Appointed Juan Vera as CEO and Monic Stuart as CMO to lead restructuring and clinical advancement.
- NIH awarded $2M SBIR grant for MT-401 AML program; EMA granted Orphan Drug Designation for MT-401.
- First lymphoma patient dosed with MT-601 in Phase 1 APOLLO trial with no treatment-related adverse events.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/0001104659-23-091425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1094038/000110465923091425/tm2323634d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-091425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer